RespireRx Pharmaceuticals — Investor Presentation (December 2018)
26 slides from RespireRx Pharmaceuticals's investor presentation, Dec 10, 2018
Slide 1: RespireRx Pharmaceuticals Inc
Pharmaceuticals Inc
Slide 2: Forward Looking Statements
Forward Looking Statements WN RespireRx eee Inc This presentation contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 (the “Exchange Act”) and the Company intends that such forward-looking
Slide 3: Understanding Neuronal Control of Respiration
Understanding Neuronal Control of Respiration FW RespireRx Pharmaceuticals Inc Breath "Breath is the universal factor of life. We are born the first time we inspire, and we die the last time we expire. Breath is life itself. In Sanskrit the same word means both breath and life." oa Abbot George Burk
Slide 4: Types of Sleep Apnea
Pharmaceuticals Inc 3 Types of Sleep Apnea Obstructive (OSA) - a peripheral phenomenon that occurs when throat muscles intermittently relax and block airway during sleep May be accompanied by snoring Central (CSA) — a brain-mediated phenomenon that occurs when breathing control centers in the brain
Slide 5: Obstructive Sleep Apnea is a National Epidemic
Obstructive Sleep Apnea is a National Epidemic oN RespireRx Pharmaceuticals Inc Estimated Annual Estimated Cost ta Annual Indicated Drug Therapy Disease State US Prevalence Society Expenditures Osa's 29.4 MM $162.0 Billion $o Asthma®’ 16.4 MM $18.3 Billion $13.5 Billion Hypertension?“ 43.2 MM $73.4
Slide 6: There are No Drug Therapies for OSA
There are No Drug Therapies for OSA DR RespireRx Current Approved Treatments Include Devices and Surgery CPAP device Dental devices In addition to the above, there are also exercises and stimulant drugs for next day sleepiness Surgery Surgical Procedures to Treat Sleep Apnea ‘SomnDent image by Ameri
Slide 7: Mean % Non-Compliance in Published RCTs
Pharmaceuticals Inc. Mean % NonCompliancein Published RCTs ‘ - \ DT t J Otolaryngol Head Neck Surg, 2016; 45: 43
Slide 8: Dronabinol: A Breakthrough Treatment for OSA
Dronabinol: A Breakthrough Treatment for DSA Resp pireRx Pharmaceuticals Inc ¢ Dronabinol is A-9-THC * Oral, small molecule ¢ Cannabinoid receptor agonist «Reduces apnea by acting on nodose ganglia controlling muscle tone in throat + Positive Phase 24 and 28 clinical trials in OSA
Slide 9: Dronabinol: A Breakthrough Treatment for OSA
Dronabinol: A Breakthrough Treatment for DSA Ad) RespireRx © Dronabinol Background = FDA approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy (Marinall®l) = Schedule Ill drug available by prescription, with a low risk of addiction
Slide 10: Translational Approach to Treating OSA
Translational Approach to Treating USA RespireRx Pharmaceuticals Inc IDENTIFY TARGET SITE: The Vagus Nerve Controls Upper Airway Muscles Pharyngeal plexus Via jugular foramen Obstructive Sleep Apnea tnpharye ‘Sensory (SA) to laryngopharynx (VA) to taste buds Motor (SE) to pharyngeal muscles: except
Slide 11: Dronabinol Works at the Nodose Ganglion to Overcome Serotonin-Induced Apnea
Dronabinol Works at the Nodose Ganglion to Overcome Serotonin-Induced Apnea . FW RespireRx Pharmaceuticals Inc Animal Model of OSA: Serotonin (SHT)-induced Reflex Apnea in Rats Dr. David Carley at the University of Illinois - Chicago Discovered the Mechanism of Action for Dronabinal in the Treatment
Slide 12: Animal Model of Sleep Apnea
Animal Model of Sleep Apnea Ad) RespireRx Pharmaceuticals Inc Polysomnographic recording of spontaneous sleep apneas in rats IP Injection of Dronabinal Attenuates SHT-Induced Reflex Apnea A°THC eee TEE RE REeR erg | TG ABT Apneas/Hour Data from Carley et af Sleep 2002 12
Slide 13: Dronabinol Works at Both CB1 & CB2 Receptors in the Nodose Ganglion
Dronabinol Works at Both CBI & CBZ Receptors in the Nodose Ganglion WN CBI (AM2Z51) and CB2 (AM630) Antagonists Block the Effects of Dronabinol on Serotonin-Induced Apnea Dronabinol 100 mg into nodose ganglion 24a c a8 Apnea Duration (s) iv. HT Data from Calik and Larley, Plas She, 2013 RespireRx Ph
Slide 14: Dronabinol Acts on Peripheral Neurons to Attenuate Apnea
Dronabinol Acts on Peripheral Neurons to Attenuate Apnea GAS) RespireRx mespirer Inc Direct Injection of Dronabinol into the Brain Does Not Alter 5-HT Induced Reflex Apnea © o ‘Apnea Duration (s) e Baseline O1ug tug _10ug__100ug DMSO ICV Dronabinol Kv from acute 5-HT-induced apnea experiments before
Slide 15: Dronabinol Proven to Reduce Apnea in OSA Subjects
Dronabinol Proven to Reduce Apnea in OSA Subjects A) RespireRx cei he a Inc Phase 2a Proof of Concept Trial of Dronabinol in OSA David Carley, University of Illinois at Chicago Apnea/Hypopnea Index (AHI) % change from baseline Dronabinol* Placebo *p.01 co 3-Week Dose-ascending Study ©. Stastical Ana
Slide 16: The PACE Clinical Trial: Phase 2B Study
THE PACE Clinical Trial: Pharmacotherapy of Apnea by Cannabimimetic Enhancement - A Phase 2B Study DW RespireRx * — Randomized, Placebo-controlled, Parallel Groups, Multi-site Trial in Patients with Moderate to Severe OSA © Study Drug: Dronabinol (Overencapsulated Marinall#): 2.5 mg or 10 mg QD + Do
Slide 17: The Phase 2B PACE Trial in OSA: Final Overall Results
The Phase 2B PACE Trial in OSA: Final Overall Results GO? RespireRx Statistically significant improvement in Primary Outcome Measures ¢ Apnea-Hypopnea Index (AHI) (2.5 and {0 mg) ¢ ESS Sleepiness Scale (10 mg) ¢ Qverall Patient Satistaction (I0 mg) 17
Slide 18: Results of 6-Week Treatment: Dronabinol Reduces AHI
Results of 6-Week Treatment: R ireR Dronabinol Reduces AHI basal thor me Positive Effects of Dronabinol vs. Placebo in TOTAL, REM & NREM Sleep Demonstrate Efficacy Change in Apnea/Hypopnealndex 10 mTST @NREM @REM Placebo 25mg/day 1Omg/day Dronabinol Dose Compared to placebo * pel * pe lld “pe 5 harm
Slide 19: Dronabinol Reduces Daytime Sleepiness
Dronabinol Reduces Daytime Sleepiness oA) RespireRx conte ita Inc Change in Epworth Sleepiness Scale _ “ : cé. nhancement * p<0.05, compared to placebo Placebo 2.5mgiday 10 mg/day pag ———— : ope Dronabinol Dose Clinical Trial 19
Slide 20: Dronabinol Improves MWT
Dronabinol Improves MWT oA) RespireRx Pharmaceuticals Inc Change in Mean Wakefulness Testing (MWT) A 12 + 10 = 8 3 6 £4 an = 2 a) 2 2 gz 4 <a .g x 8 *k “40 pAGe= harmacotherapy of Placebo 2.5mg/day 10 mg/day Clinical Trial Dronabinol Dose 20
Slide 21: Patients are Highly Satisfied With Treatment
RespireRx o_o Inc Patients are Highly Satisfied With Treatment TSQM Response. End of Treatment * * p-0.04 for Treatment Effect 21
Slide 22: Dronabinol Has an Excellent Safety Profile
Dronabinol Has an Excellent Safety Profile C : RespireRx conte ita Inc Great Majority of AEs were mild to moderate + Average Number of AEs = 4.1:4.0 + AEs did not differ by treatment group ¢ Most Frequent Verbatim AEs Reported Were: - Sleepiness/Drowsiness (N=25) - Headache (N=24) - Nausea/Vomiting
Slide 23: Two Successful Phase 2 Studies - Phase 3 Ready
Two Successful Phase 2 Studies - Phase 3 Ready GAS) RespireRx conte ita Inc Two Phase 2 Clinical Trials Have Shown That Dronabinol Treatment Results in Statistically Significant, Dose Related Improvements in AHI, a Primary Endpoint for FDA Approval *** p<.0, compared ta placeba for Phase 7A, = < x S
Slide 24: Dronabinol - Phase 3 Regulatory Strategy
Dronabinol - Phase 3 Regulatory Strategy~ GQ RespireRx Meet with FDA during Q1/2015 Finalize the Phase 3 trial plan required tor approval Position dronabinol as a breakthrough medicine Seek fast track designation Facilitate and hasten the development path * Subject to available financing, of which n
Slide 25: Dronabinol: A Breakthrough Treatment for OSA
Dronabinol: A Breakthrough Treatment for OSA BR RespireRx Pharmaceuticals Inc ©. Dronabinal Overview = — Rx drug approved for the treatment of anorexia in AIDS patients and nausea and vomiting in cancer patients undergoing chemotherapy = Marinoll & Generic Manufacturers Market 2.5, 5, 10 mg gel caps
Slide 26: Pharmaceuticals Inc
Pharmaceuticals Inc
RespireRx Pharmaceuticals — Investor Presentation (December 2018) on 6ix